Psoriasis (ARTISTYK Study)

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Condition or Disease

Psoriasis

Study Design

Study Type:	Interventional
Estimated Enrollment:	250 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
Actual Study Start Date:	January 2023
Estimated Primary Completion Date:	April 2024
Estimated Study Completion Date:	January 2025

Eligibility Criteria

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Inclusion Criteria

Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. Deemed by the investigator to be a candidate for phototherapy or systemic therapy. ≥ 3% of Body Surface Area (BSA) involvement at Screening Visit and Day 1 Dermatology Life Quality Index (DLQI) score > 5 at Screening Visit and Day 1

Exclusion Criteria

Target Disease Exceptions: Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1 Other protocol-defined inclusion/exclusion criteria apply.

ADDITIONAL DETAILS

Application for Clinical Trials

Name(Required)

First Name Last Name

Phone(Required)

Email(Required)

Birthday(Required)

Select a State(Required)

Select a Condition (Arizona)(Required)

Select a Condition (Kansas)(Required)

Select a Condition (Maryland)(Required)

Select a Condition (Missouri)(Required)

Select a Condition (Texas)(Required)

Select a Clinical Trial: Actinic Keratosis (Arizona)(Required)

Select a Clinical Trial: Alopecia Areata (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Arizona)(Required)

Select a Clinical Trial: Atopic Dermatitis (Texas)(Required)

Select a Clinical Trial: Atopic Dermatitis (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Missouri)(Required)

Select a Clinical Trial: Atopic Dermatitis (Kansas)(Required)

Select a Clinical Trial: Bullous Pemphigoid (Arizona)(Required)

Select a Clinical Trial: Hidradenitis Suppurativa (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Arizona)(Required)

Select a Clinical Trial: Psoriasis (Texas)(Required)

Select a Clinical Trial: Psoriasis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Missouri)(Required)

Select a Clinical Trial: Psoriasis (Kansas)(Required)

Select a Clinical Trial: Skincare (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Missouri)(Required)

Select a Clinical Trial: Skin Cancer (Maryland)(Required)

How did you hear about us?(Required)

Message(Required)

CAPTCHA

Name

This field is for validation purposes and should be left unchanged.

Menu

Study Description

Brief Summary

Condition or Disease

Study Design

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Application for Clinical Trials

ACTIVE TRIALS

LOCATIONS

NAVIGATION

SOLUTIONS